Greenwich LifeSciences Announces Exercise and Closing of Underwriter’s Over-Allotment Option
January 29 2021 - 11:33AM
Business Wire
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a
clinical-stage biopharmaceutical company focused on the development
of GP2, an immunotherapy to prevent breast cancer recurrences in
patients who have previously undergone surgery, today announced
that the underwriter of its previously announced underwritten
public offering has exercised its option and purchased an
additional 70,000 shares of common stock at a price of $40.00 per
share. Total gross proceeds to the Company from the offering,
including the funds received from the prior closing and exercise of
this option, are approximately $29.2 million, before deducting
underwriting discounts, commissions and other offering expenses
payable by the Company.
Aegis Capital Corp. acted as sole bookrunner for the
offering.
A registration statement relating to the shares of common stock
being sold in this offering was declared effective by the
Securities and Exchange Commission (the “SEC”) on December 17,
2020. The offering is being made only by means of a prospectus.
Copies of the final prospectus may be obtained on the SEC's
website, www.sec.gov, or by contacting Aegis Capital Corp.,
Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New
York, NY 10019, by email at syndicate@aegiscap.com, or by telephone
at (212) 813-1010.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical
company focused on the development of GP2, an immunotherapy to
prevent breast cancer recurrences in patients who have previously
undergone surgery. GP2 is a 9 amino acid transmembrane peptide of
the HER2/neu protein. In a randomized, single-blinded,
placebo-controlled, multi-center (16 sites led by MD Anderson
Cancer Center) Phase IIb clinical trial, no recurrences were
observed in the HER2/neu 3+ adjuvant setting after median 5 years
of follow-up, if the patient received the 6 primary intradermal
injections over the first 6 months (p = 0.0338). Of the 138
patients that have been treated with GP2 to date over 4 clinical
trials, GP2 treatment was well tolerated and no serious adverse
events were observed related to GP2 immunotherapy. Greenwich
LifeSciences is planning to commence a Phase III clinical trial
using a similar treatment regime as the Phase IIb clinical trial.
For more information on Greenwich LifeSciences, please visit the
company’s website: www.greenwichlifesciences.com
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Greenwich LifeSciences Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict, including statements
regarding the completion of the public offering, the satisfaction
of customary closing conditions related to the public offering and
the intended use of net proceeds from the public offering;
consequently, actual results may differ materially from those
expressed or implied by such forward-looking statements. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled “Risk Factors” in the final prospectus related to the public
offering filed with the Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date, and Greenwich LifeSciences Inc. undertakes no duty
to update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210129005454/en/
Company Contact Snehal Patel Investor Relations (832)
819-3232 info@greenwichlifesciences.com Investor &
Public Relations Contact for Greenwich LifeSciences Dave Gentry
RedChip Companies Inc. Office: 1-800-RED CHIP (733 2447) Cell:
(407) 491-4498 dave@redchip.com
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024